Zimmer Biomet has begun a deal to acquire Monogram Technologies for upfront payment of about $4.04 a share, reflecting an equity value of about $177 million and an enterprise value of about $168 million.

Monogram’s semi- and fully autonomous robotic technologies will add new, differentiated capabilities to expand Zimmer Biomet’s ROSA robotics platform and suite of navigation and enabling technologies. Monogram developed a CT-based, semi-autonomous, artificial intelligence (AI)-navigated total knee arthroplasty (TKA) robotic technology.

The tech earned U.S. Food and Drug Administration (FDA) 510(k) clearance in March 2025 and is expected to be sold with Zimmer Biomet implants in early 2027.

Monogram is also developing a fully autonomous version of the tech, which has potential for additional applications beyond TKA. Once the transaction is complete, Zimmer Biomet expects a clear pathway to become the first, only company in orthopedics with a fully autonomous surgical robot.

Zimmer Biomet’s broad portfolio features imageless robotics through its ROSA platform; a licensed CT-based handheld robot; mixed reality navigation; AI-based surgical navigation; and a pathway to advanced semi- and fully autonomous robotics capabilities. The ROSA platform, which is the cornerstone of Zimmer Biomet’s robotics offering, is quickly approaching 2,000 installations worldwide and is a market leader outside of the U.S.

The company plans to feature several product and software applications for ROSA between now and 2027. This includes ROSA Knee with OptimiZe, which has been submitted to the FDA and 510(k) clearance is anticipated later this year, as well as ROSA Posterior Hip and the full commercial launch of ROSA Shoulder.

“Monogram’s technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation,” said Ivan Tornos, Chairman, president and CEO of Zimmer Biomet. “Upon closing, our customer-centric portfolio will consist of the most comprehensive and flexible technology ecosystem to support the varying preferences of a vast array of surgeons—now and into the future. With Monogram’s proprietary technology, Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery.”

The merger is expected to close later this year.

“Since our inception, we have been singularly focused on advancing orthopedic robotics with technology designed to safely, efficiently and accurately support surgeons with total knee arthroplasty,” said Benjamin Sexson, CEO of Monogram. “We are thrilled by the opportunity to add our technology to Zimmer Biomet’s leading portfolio of surgical robotics, navigation solutions and trusted implants and to benefit from their deep industry expertise and global scale.”